Here is a list of stocks with an above 10% expected next quarter sales growth, and a 3% or higher return on equity. May these stocks be a good medium-term investment option?
Maxim Integrated Products, Inc. designs, develops, manufactures, and markets a range of linear and mixed-signal integrated circuits in the United States, China, rest of Asia, Europe, and internationally.
Maxim Integrated Products, Inc.s sales growth this year is anticipated to be 13% and 5.2% for next year.
Year-on-year quarterly revenue growth grew by 16.2%, now sitting on 2.28B for the twelve trailing months.
Maxim Integrated Products, Inc.s sales growth for the next quarter is 9.6%. The companys growth estimates for the present quarter and the next is 21.4% and 13.1%. The companys return on equity, which measures the profitability of a business relative to shareholders equity, for the twelve trailing months is 39.17%.
Maxim Integrated Products, Inc.s last day, last week, and last months average volatility was 1.03%, 1.75%, and 0.56%, respectively.
Maxim Integrated Products, Inc.s last day, last week, and last months high and low average amplitude percentage was 2.58%, 3.49%, and 2.22%, respectively.
Maxim Integrated Products, Inc.s stock is valued at $95.38 at 04:22 EST, under its 52-week high of $96.71 and way above its 52-week low of $41.93.
Maxim Integrated Products, Inc.s worth is way above its 50-day moving average of $86.05 and way higher than its 200-day moving average of $73.54.
Mr. Cooper Group Inc. provides servicing, origination, and transaction-based services related principally to single-family residences in the United States.
Mr. Cooper Group Inc.s sales growth this year is expected to be 31.9% and 3.4% for next year.
Year-on-year quarterly revenue growth grew by 41.1%, now sitting on 2.52B for the twelve trailing months.
Mr. Cooper Group Inc.s sales growth for the next quarter is 95.4%. The companys growth estimates for the ongoing quarter and the next is 130.1% and 83.8%. The companys return on equity, which measures the profitability of a business relative to shareholders equity, for the twelve trailing months is 28.09%.
Mr. Cooper Group Inc.s last day, last week, and last months average volatility was 1.89%, 0.04%, and 0.41%, respectively.
Mr. Cooper Group Inc.s last day, last week, and last months high and low average amplitude percentage was 2.41%, 3.41%, and 3.73%, respectively.
Mr. Cooper Group Inc.s stock is valued at $29.50 at 04:22 EST, under its 52-week high of $31.52 and way higher than its 52-week low of $4.31.
Mr. Cooper Group Inc.s value is above its 50-day moving average of $28.80 and way above its 200-day moving average of $21.73.
iRobot Corporation designs, builds, and sells robots to the consumer market in the United States, Europe, the Middle East, Africa, and internationally.
iRobot Corporations sales growth this year is anticipated to be 12.9% and 7.3% for next year.
Year-on-year quarterly revenue growth grew by 42.8%, now sitting on 1.31B for the twelve trailing months.
iRobot Corporations sales growth for the next quarter is 23%. The companys growth estimates for the present quarter and the next is a negative 70% and 75%. The companys return on equity, which measures the profitability of a business relative to shareholders equity, for the twelve trailing months is 21.89%.
iRobot Corporations last day, last week, and last months average volatility was a negative 1.25%, a positive 0.93%, and a positive 0.36%, respectively.
iRobot Corporations last day, last week, and last months high and low average amplitude percentage was 3.57%, 4.66%, and 4.07%, respectively.
iRobot Corporations stock is valued at $86.35 at 04:22 EST, way under its 52-week high of $98.55 and way above its 52-week low of $32.79.
iRobot Corporations worth is above its 50-day moving average of $80.31 and higher than its 200-day moving average of $79.43.
Halozyme Therapeutics, Inc. operates as a biopharma technology platform company in the United States, Switzerland, and internationally.
Halozyme Therapeutics, Inc.s sales growth this year is expected to be 35.4% and 52.2% for next year.
Year-on-year quarterly revenue growth grew by 41.3%, now sitting on 199.56M for the twelve trailing months.
Halozyme Therapeutics, Inc.s sales growth for the next quarter is 281.6%. The companys growth estimates for the present quarter and the next is 316.7% and 1025%. The companys return on equity, which measures the profitability of a business relative to shareholders equity, for the twelve trailing months is 12.5%.
Halozyme Therapeutics, Inc.s last day, last week, and last months average volatility was a negative 2.96%, a positive 0.41%, and a positive 0.10%, respectively.
Halozyme Therapeutics, Inc.s last day, last week, and last months high and low average amplitude percentage was 6.52%, 4.77%, and 4.07%, respectively.
Halozyme Therapeutics, Inc.s stock is valued at $43.57 at 04:22 EST, under its 52-week high of $45.76 and way above its 52-week low of $12.71.
Halozyme Therapeutics, Inc.s worth is above its 50-day moving average of $41.72 and way above its 200-day moving average of $32.13.
Alexion Pharmaceuticals, Inc. develops and commercializes various therapeutic products.
Alexion Pharmaceuticals, Inc.s sales growth this year is expected to be 20.8% and 9.2% for next year.
Year-on-year quarterly revenue growth grew by 25.8%, now sitting on 5.86B for the twelve trailing months.
Alexion Pharmaceuticals, Inc.s sales growth for the next quarter is 9.5%. The companys growth estimates for the present quarter and the next is a negative 5.5% and negative -3.7%. The companys return on equity, which measures the profitability of a business relative to shareholders equity, for the twelve trailing months is 8.92%.
Alexion Pharmaceuticals, Inc.s last day, last week, and last months average volatility was 1.03%, 0.14%, and 1.49%, respectively.
Alexion Pharmaceuticals, Inc.s last day, last week, and last months high and low average amplitude percentage was 0.85%, 1.22%, and 1.47%, respectively.
Alexion Pharmaceuticals, Inc.s stock is valued at $157.35 at 04:22 EST, below its 52-week high of $160.03 and way above its 52-week low of $72.67.
Alexion Pharmaceuticals, Inc.s value is way above its 50-day moving average of $140.79 and way above its 200-day moving average of $119.39.
Newmont Corporation engages in the production and exploration of gold, copper, silver, zinc, and lead.
Newmont Mining Corporations sales growth this year is expected to be 17.9% and 22.8% for next year.
Year-on-year quarterly revenue growth grew by 16.8%, now sitting on 11.08B for the twelve trailing months.
Newmont Mining Corporations sales growth for the next quarter is 44%. The companys growth estimates for the ongoing quarter and the next is 90% and 162.5%. The companys return on equity, which measures the profitability of a business relative to shareholders equity, for the twelve trailing months is 10.48%.
Newmont Mining Corporations last day, last week, and last months average volatility was 2.70%, 0.33%, and 0.15%, respectively.
Newmont Mining Corporations last day, last week, and last months high and low average amplitude percentage was 3.32%, 2.48%, and 2.41%, respectively.
Newmont Mining Corporations stock is valued at $63.52 at 04:22 EST, way under its 52-week high of $72.22 and way above its 52-week low of $33.00.
Newmont Mining Corporations value is higher than its 50-day moving average of $60.99 and above its 200-day moving average of $63.41.
Rollins, Inc., through its subsidiaries, provides pest and termite control services to residential and commercial customers.
Rollins, Inc.s sales growth this year is anticipated to be 6.9% and 6.7% for next year.
Year-on-year quarterly revenue growth grew by 4.9%, now sitting on 2.13B for the twelve trailing months.
Rollins, Inc.s sales growth for the next quarter is 5.7%. The companys growth estimates for the ongoing quarter and the next is 18.2% and 22.2%. The companys return on equity, which measures the profitability of a business relative to shareholders equity, for the twelve trailing months is 28.62%.
Rollins, Inc.s last day, last week, and last months average volatility was 1.57%, 0.87%, and 0.38%, respectively.
Rollins, Inc.s last day, last week, and last months high and low average amplitude percentage was 1.77%, 3.13%, and 3.15%, respectively.
Rollins, Inc.s stock is valued at $40.80 at 04:22 EST, below its 52-week high of $43.00 and way higher than its 52-week low of $20.48.
Rollins, Inc.s value is above its 50-day moving average of $38.50 and way above its 200-day moving average of $36.38.
Follow this link:
Rollins, Inc. And 6 Other Stocks Have High Sales Growth And An Above 3% Return on Equity - Via News Agency